Cysteamine is a small, naturally occurring molecule in the human body that plays a role in several metabolic processes. Chemically classified as 2-aminoethanethiol, it contains both a sulfur-containing thiol group and an amino group, which together give it unusual reactivity. This simple structure makes it useful in medicine, where it treats a rare genetic kidney disease and, more recently, skin discoloration.
How Cysteamine Works in the Body
Your cells produce cysteamine as a byproduct of coenzyme A breakdown, a molecule involved in energy metabolism. It participates in two key metabolic pathways: the production of taurine (an amino acid important for heart and brain function) and the biosynthesis of coenzyme A itself. Its sulfur-containing thiol group is what makes it biologically active, allowing it to react with and break apart certain chemical bonds that other molecules cannot.
The most medically important thing cysteamine does is break down cystine, an amino acid that can accumulate inside cellular compartments called lysosomes. In a healthy cell, cystine gets transported out of lysosomes without issue. But in people with the genetic condition cystinosis, that transport system is broken, and cystine builds up into crystals that damage organs. Cysteamine enters the lysosome and splits cystine into two products: cysteine and a cysteamine-cysteine compound. Both of these can slip through the lysosomal membrane using a different transport route, essentially bypassing the broken one. Research in white blood cells showed that cystine on its own barely exits cystinotic lysosomes, with half-times of 199 to 293 minutes. The cysteamine-cysteine compound, by contrast, exits with half-times of just 66 to 88 minutes.
Treating Cystinosis
Nephropathic cystinosis is a rare inherited disease that primarily damages the kidneys but can also affect the eyes, muscles, and brain. Without treatment, children with cystinosis typically develop kidney failure. Cysteamine bitartrate (a salt form that the body can absorb) is the standard treatment and the only one that directly addresses the underlying problem of cystine buildup.
Two oral formulations are available. Cystagon is an immediate-release capsule that patients take every six hours. Procysbi, a delayed-release capsule approved by the FDA in April 2013, is taken every twelve hours, which makes the dosing schedule more manageable. Procysbi was initially approved for adults and children aged six and older, then extended in August 2015 to include children as young as two. The standard dosing target is 1.3 grams per square meter of body surface area per day for patients under 50 kilograms, and 2 grams per day for those above that weight, with a maximum of 1.95 grams per square meter per day.
Cysteamine eye drops are also used to dissolve the cystine crystals that form in the corneas of people with cystinosis, a separate but related problem. The drug converts corneal cystine into cysteine and the mixed disulfide, clearing the crystals over time.
Side Effects of Oral Cysteamine
The most common side effects, reported in more than 5% of patients, are vomiting, abdominal pain, headaches, nausea, diarrhea, decreased appetite, fatigue, dizziness, and rash. Two side effects stand out as particularly bothersome: a sulfur-like odor on the breath and skin. This smell comes from cysteamine’s thiol group and is difficult to mask.
More serious but less common effects involve the central nervous system. Some patients experience seizures, severe drowsiness, depression, or encephalopathy (a general decline in brain function). Gastrointestinal ulceration and bleeding have also been reported. These risks are generally managed through careful dose adjustments.
Treating Skin Discoloration
Beyond its role in cystinosis, cysteamine has gained attention as a topical treatment for melasma, the patchy brown discoloration that commonly appears on the face. It works through several mechanisms at once. It inhibits tyrosinase, the key enzyme that drives melanin production in skin cells. It also shifts the type of melanin your skin makes, pushing production away from the darker eumelanin toward the lighter pheomelanin by raising levels of glutathione inside cells. On top of that, cysteamine scavenges dopaquinone, a precursor molecule in the pigment-making pathway, and chelates iron and copper ions that contribute to pigment formation.
The standard formulation is a 5% cysteamine hydrochloride cream applied once daily, typically at night. You apply it to unwashed skin (or at least one hour after washing), leave it on for 15 to 30 minutes, then rinse it off with water. Sunscreen use during the day is essential alongside treatment.
In clinical trials comparing 5% cysteamine cream to 4% hydroquinone (the traditional gold-standard treatment for melasma), hydroquinone showed stronger results on standardized scoring: a 53% reduction in melasma severity scores at 120 days compared to 38% for cysteamine. However, when physicians evaluated before-and-after photographs, both treatments showed up to 74% improvement with no statistically significant difference between them. This makes cysteamine an appealing option for people who want to avoid hydroquinone, which carries risks of rebound darkening and skin irritation with long-term use.
The Odor and Stability Problem
One of the biggest practical challenges with cysteamine, whether oral or topical, is its smell. The sulfhydryl group responsible for its biological activity also produces a strong, unpleasant sulfur odor that perfumes cannot cover. The molecule is also chemically unstable in solution, rapidly oxidizing when exposed to air and converting into cystamine, its inactive oxidized form. This instability makes it difficult to formulate into products that stay effective on the shelf.
Researchers have addressed these issues through encapsulation technologies, including liposomes, cyclodextrin complexes, and emulsion systems. Cyclodextrin-based formulations have been particularly successful at reducing odor, while emulsion systems improve stability. Recent pharmaceutical developments have produced stabilized topical formulations that keep the molecule active longer and reduce the smell enough to make the product tolerable for daily use, though the odor remains noticeable.
Radiation Protection
Cysteamine was actually studied as a radiation-protective agent before it became a cystinosis treatment. Its thiol group scavenges free radicals, the highly reactive molecules that ionizing radiation generates inside cells. This neutralizes what scientists call the “indirect effects” of radiation, where the damage comes not from the radiation beam itself but from the chemical chain reactions it triggers in surrounding water and tissue. Cysteamine also provides some protection against direct radiation damage, though this effect is weaker. Even low concentrations have been shown to provide meaningful protection against chronic radiation exposure from radionuclides incorporated into tissue, making it distinct from agents that only work against acute, external radiation beams. While this application remains largely experimental, it highlights the molecule’s versatility as a biological shield against oxidative damage.